Date
9 April 2025Location
Online via Webex, 12.30-2pmAbout the event
Speakers from NHS England and NHS SPS provided an update about biosimilar and key generic medicines expected in 2025/26. There was a focus on aflibercept, golimumab, nilotinib and ferric carboxymaltose, and an opportunity was provided to ask questions and share experience.
This webinar was intended for NHS procurement and clinical teams who will be implementing upcoming biosimilar and high value generic medicines. It was not recorded as some information is commercially confidential and subject to change.
Why it’s important
Implementation of biosimilar and key generic medicines requires collaborative working across the system. The use of biological medicines, including biosimilars, in clinical practice is expanding. Timely implementation and use of biosimilar and key generic medicines offers the NHS opportunities to deliver better value for certain conditions.
What was covered
Updated information to support planning and implementation for upcoming biosimilar and key generic medicines, specifically aflibercept, golimumab, nilotinib and ferric carboxymaltose.
There was an opportunity to ask questions of NHSE and NHS SPS colleagues. Additional time was added to the session to extend the Q&A for those who could attend.
Speakers
A range of speakers from SPS and other organisations helped run this event.
Non-SPS speakers
Bhavana Reddy
Head of Pharmacy and Clinical Support, Pharmacy and Clinical Support Team, Medicines Value and Access, NHS England
SPS speakers
Resources
This event was not recorded as some information is commercially confidential and subject to change.
Future webinars
We plan to hold update webinars on the following dates:
- Wednesday 9 July 2025
- Thursday 11 September 2025
- Wednesday 10 December 2025
Save these dates in your diaries and look out for further information nearer the time.
Contact us
Please contact the admin team if you have any questions.